← Oncology Approval Tracker

FDA DECISION ·

Sunitinib (generic Sutent)

sunitinib malate · Sun Pharmaceutical Industries

First generic approvalFirst genericRenal cell carcinoma, GIST and pancreatic neuroendocrine tumors
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

First generic Sutent capsules for adults with advanced renal cell carcinoma, adjuvant use after nephrectomy for renal cell carcinoma at high risk of recurrence, GIST after imatinib progression or intolerance, or progressive well-differentiated pancreatic neuroendocrine tumors that are unresectable locally advanced or metastatic.

LAMPGEN ANALYSIS

Why it matters

The generic approval covers distinct disease and treatment settings for the same kinase inhibitor.

What research teams should watch

Document the relevant indication and reconcile capsule strength and dosing schedule for each setting.

PRIMARY RECORDS

Sources